Registry of Biological/Targeted Therapy BIOREP
– Summary Report 2020

Czech version

Authors: M. Kojanová ¹; J. Fialová ¹; S. Gkalpakiotis ²; P. Cetkovská ³; J. Štork ¹; P. Arenberger ²; A. Machovcová ⁴; T. Doležal ⁵; B. Velacková ⁵; Biorep Skupina
Authors‘ workplace: Dermatovenerologická klinika Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy, Praha, přednosta prof. MUDr. Jiří Štork, CSc. ¹; Dermatovenerologická klinika Fakultní nemocnice Královské Vinohrady a 3. lékařské fakulty Univerzity Karlovy, Praha, přednosta prof. MUDr. Petr Arenberger, DrSc., MBA ²; Dermatovenerologická klinika Fakultní nemocnice a Lékařské fakulty Univerzity Karlovy v Plzni, přednosta prof. MUDr. Karel Pizinger, CSc. ³; Dermatovenerologické oddělení Fakultní nemocnice v Motole a 2. lékařské fakulty Univerzity Karlovy, Praha, primář MUDr. Alena Machovcová, Ph. D., MBA ⁴; Value Outcomes, Praha ⁵
Published in: Čes-slov Derm, 96, 2021, No. 1, p. 17-34
Category: Pharmacologyand Therapy, Clinical Trials

Overview

Background and objectives: Evaluation of patients included in the registry of biological/targeted therapy BIOREP in the Czech Republic in 2020.

Methods: A retrospective evaluation of patients enrolled in the BIOREP registry to date 31 December 2020 was performed. The objects of our study were patients on biological/targeted treatment in the given period in each category and the evaluation of the population of patients with psoriasis and hidradenitis.

Results: As of 31 December 2020, a total of 3121 patients were registered in the BIOREP registry: 2870 (92.0%) patients with psoriasis, 243 (7.8%) with hidradenitis and 8 (0.3%) treated with off label treatment. In the psoriasis group, 63.6% of patients were men. The average age of patients at the end of 2020 was 51.8 years, the mean age at the time of diagnosis was 24.8 years, and the age at the time of first biological/targeted treatment was 46.1 years. In 2020, the average time from diagnosis to the introduction of biological treatment was 21.4 years, the average duration of biological/targeted treatment was 5.4 years. Comorbidities occurred in 72.2% of patients, mostly metabolic/endocrine diseases (53.8%) and cardiovascular diseases (53.2%), more specifically hypertension (50.6%), dyslipidemia (38.6%) and diabetes mellitus (13.3%) were the most common. More than 75% of patients were overweight or obese and 31.6% of patients were smokers. Psoriatic arthritis was observed in 35.1% of patients. At the start of the treatment and at the last visit, the mean PASI was 18.8 and 3.0, respectively and DLQI 16.4 and 2.4 respectively. In 2020, a total of 366 patients newly started treatment. As of 31 December 2020, there were 243 patients with hidradenitis suppurativa in the registry, 52.3% were men and the mean age was 45 years. The mean age at the time of diagnosis was 34.2 years and the age at the time of the initiation of the first biological treatment was 43.2 years. The average time from diagnosis to the start of the biological treatment was 9.0 years and patients were treated for an average of 2.1 years. In 2020, a total of 52 patients started the biological treatment. At the end of 2020, a total of 206 patients were treated and the average duration of treatment with one medication was 2.2 years.

Conclusion: BIOREP is the first registry of patients for biological treatment of psoriasis in Central and Eastern Europe. The results, when compared to European registries, show a comparable or higher prevalence of co-morbidities and risk factors and a long period of inadequate treatment before initiating biologic therapy.

Keywords:

Psoriasis – Hidradenitis suppurativa – biological therapy – registries – BIOREP

Sources

1. AMIN, M., LEE, E. B., BHUTANI, T. et al. Review of European registries for psoriasis. J Dermatol Treat., 2019, 3, p. 227–236.

2. AUGUSTIN, M., SPEHR, C., RADTKE, M. A. et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges, 2014, 12, p. 48–57.

3. BELINCHÓN, I., RAMOS, J. M., CARRETERO, G. et al. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. J Eur Acad Dermatol Venereol., 2017, 10, p. 1700–1708.

4. COSTANZO, A., MALARA, G., PELUCCHI, C. et al. Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival. Dermatol Basel Switz., 2018, 234, p. 1–12.

5. EGEBERG, A., OTTOSEN, M. B., GNIADECKI R. et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol., 2018, 2, p. 509–519.

6. KLIJN, S. L., VAN DEN REEK, J. M. P. A., VAN DEN WETERING, G. et al. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. Br J Dermatol., 2018, 5, p. 1181–1189.

7. MOURAD, A., STRAUBE, S., ARMIJO-OLIVO, S. et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol., 2019, 3, p. 450–458.

8. POGÁCSÁS, L., BORSI, A., TAKACS, P. et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatol Treat., 2017, 7, p. 635–641.

9. STROBER, B., CROWLEY, J., LANGLEY, R. G. et al. Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. J Eur Acad Dermatol Venereol., 2018, 12, p. 2126–2133.

10. VILARRASA, E., NOTARIO, J., BORDAS, X. et al. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol, 2016, 6, p. 1066–1072.

11. WARREN, R. B., MARSDEN, A., TOMENSON, B. et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol., 2019, 5, p. 1069–1076.

12. YIU, Z. Z. N., MASON, K. J., HAMPTON, P. J. et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol., 2020, 2, p. 294 to 302.